Bryan K Kee, M.D.

Peer-Reviewed Articles

1. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-challenge. Ann Oncol. e-Pub 2018. PMID: 30462160.
2. Brusco LL, Wathoo C, Mills Shaw KR, Holla VR, Bailey AM, Johnson AM, Khotskaya YB, Litzenburger BC, Sanchez NS, Zeng J, Bernstam EV, Eng C, Kee BK, Amaria RN, Routbort MJ, Mills GB, Mendelsohn J, Meric-Bernstam F. Physician interpretation of genomic test results and treatment selection. Cancer 124(5):966-972, 2018. e-Pub 2017. PMID: 29165790.
3. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic R, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 29(1):139-144, 2018. e-Pub 2017. PMID: 29069279.
4. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget 8(24):39268-39279, 2017. PMID: 28424412.
5. Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Ann Oncol 28(3):642-650, 2017. PMID: 27993791.
6. Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(3):e0173345, 2017. e-Pub 2017. PMID: 28267766.
7. Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris V. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One 12(8):e0183949, 2017. e-Pub 2017. PMID: 28850629.
8. Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol 2017, 2017. e-Pub 2017. PMID: 29082359.
9. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov 6(12):1352-1365, 2016. e-Pub 2016. PMID: 27729313.
10. Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, Lutterbaugh J, Issa JP, Markowitz SD, Kopetz S. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget 7(41):67495-67506, 2016. e-Pub 2016. PMID: 27542211.
11. Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol 27(6):1068-74, 2016. e-Pub 2016. PMID: 27045102.
12. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther 15(6):1397-404, 2016. e-Pub 2016. PMID: 27207774.
13. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(27):24581, 2015. PMID: 26405159.
14. Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs 33(4):911-20, 2015. e-Pub 2015. PMID: 25990659.
15. Al-Shamsi HO, Kee BK, Tetzlaff MT, Wolff RA. Capecitabine-induced leukocytoclastic vasculitis under neoadjuvant chemotherapy for locally advanced colorectal cancer. J Gastrointest Oncol 6(3):E40-3, 2015. PMID: 26029464.
16. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6(14):12809-21, 2015. PMID: 25980577.
17. Morris V, Overman MJ, Jiang ZQ, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colrectal Cancer 13(3):164-71, 2014. PMID: 25069797.
18. Kee BK, Morris JS, Slack RS, Crocenzi T, Wong L, Esparaz B, Overman M. Glover K, Jones D, Wen S, Fisch MJ. A Phase II randomized bouble blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Support Care Cancer. e-Pub 2014. PMID: 25160493.
19. Subbiah IM, Blackmon SH, Correa AM, Kee B, Vaporciyan AA, Swisher SG, Eng C. Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. Oncotarget 5(16):6584-93, 2014. PMID: 25051371.
20. Tanasanvimon S, Garg N, Viswanathan C, Truong M, Kaur H, Kee BK, Sahin IH, Javle MM, Garrett CR. High prevalence of recurrent thrombosis in subsets of cancer patients with isolated gonadal vein thrombosis: a single center retrospective study. Thromb Res 133(2):154-7, 2014. PMID: 24331209.
21. Sahin IH, Kazmi SM, Yorio JT, Bhadkamkar NA, Kee BK, Garrett CR. Rare though not mutually exclusive: a report of three cases of concomitant KRAS and BRAF mutation and a review of the literature. J Cancer 4(4):320-322, 2013. e-Pub 2013. PMID: 23569465.
22. Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C. Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. Clin Colorectal Cancer 11(3):191-4, 2012. e-Pub 2012. PMID: 22280844.
23. Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, Eng C, Hassan MM. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer 106(8):1374-8, 2012. e-Pub 2012. PMID: 22421948.
24. Yorio JT, Bhadkamkar NA, Kee BK, Garrett CR. A Primer on the Current State-of-the-Science Neoadjuvant and Adjuvant Therapy for Patients with Locally Advanced Rectal Adenocarcinomas. Int J Surg Oncol 2012:863034, 2012. e-Pub 2012. PMID: 22666572.
25. Arnold SM, Rinehart JJ, Tsakalozou E, Eckardt JR, Fields SZ, Shelton BJ, DeSimone PA, Kee BK, Moscow JA, Leggas M. A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies. Clin Cancer Res 16(2):673-80, 2010. e-Pub 2010. PMID: 20068096.

Abstracts

1. Kanwal Pratap Singh Raghav, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Bryan K. Kee, Andrea Muranyi, Shalini Singh, Mark Routbort, Ken Chen, Kenna Rael Shaw, Kandavel Shanmugam, Dipen M. Maru, Marwan Fakih, Scott Kopetz; The University of Texas MD Anderson Cancer Center, Houston, TX; Ventana Medical Systems, Inc., Tucson, AZ; City of Hope, Duarte, CA. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol 34, 2016.
2. Callisia Clarke, Krittiya Korphaisarn, Zhiqin Jiang, Shadarra Crosby, Darren W. Davis, Weiguo Wu, Kanwal Pratap Singh Raghav, Michael J. Overman, Van Karlyle Morris, Bryan K. Kee, Cathy Eng, David R. Fogelman, Nicholas Navin, Scott Kopetz; The University of Texas MD Anderson Cancer Center, Houston, TX; Siriraj Hospital, Bangkok, Thailand; The University of Texas MD Anderson Cancer Center, Sugar Land, TX; Apocell Inc, Houston, TX; ApoCell Inc, Houston, TX. Antibody-independent isolation and characterization of circulating tumor cells using dielectrophoresis: Fluid flow fractionation in metastatic colorectal cancer. J Clin Oncol 34, 2016.
3. Krittiya Korphaisarn, Michael J. Overman, David R. Fogelman, Bryan K. Kee, Kanwal Pratap Singh Raghav, Imad Shureiqui, Robert A. Wolff, Keyur Patel, Kenna Rael Shaw, Cathy Eng, Dipen M. Maru, Mark Routbort, Funda Meric-Bernstam, Scott Kopetz, Van Karlyle Morris, Eduardo Vilar-Sanchez, Shanequa Manuel, A. Dasari. Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts). J Clin Oncol 34, 2016.
4. A. Dasari, Michael J. Overman, David R. Fogelman, Bryan K. Kee, David Menter, Kanwal Pratap Singh Raghav, Van Karlyle Morris, Jisu Oh, Ji Wu, Zhiqin Jiang, Feng Tian, Liana Adam, Mary Brimer, Jeffrey Morris, Funda Meric-Bernstam, Scott Kopetz;. A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC). J Clin Oncol 34, 2016.
5. Michael J. Overman, Bryan K. Kee, David R. Fogelman, Cathy Eng, Eduardo Vilar Sanchez, Rachna T. Shroff, Arvind Dasari, Robert A. Wolff, Jeffrey Morris, Scott Kopetz. A phaseII Study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer. J Clin Oncol 33(suppl), 2015.
6. M. Pia Morelli, Michael J. Overman, Bryan K. Kee, Eduardo Vilar Sanchez, Van Karlyle Morris, David R. Fogelman, Filip Janku, Chris R. Garrett, Imad Shureiqi, Kanwal Pratap Singh Raghav, Cathy Eng, Shanequa Manuel, Robert A. Wolff, Helmy Eltoukhy, Richard Burnham Lanman, AmirAli Talasaz, Scott Kopetz. Predictors of clonal evolution in metastatic colorectal cancer patients. J Clin Oncol 33(suppl), 2015.
7. Karen Basen-Engquist, Patricia A. Parker, Cathy Eng, Yisheng Li, David B. Johnson, Bryan K. Kee, Sajeve Samuel Thomas, Lucas Wong, Todd S. Crocenzi, Jaejoon Song, Michael Fisch. Randomized trial of a home-based exercise intervention for patients with advanced colorectal cancer: Effects on physical functioning and activity levels. J Clin Oncol 33(suppl), 2015.
8. Van Karlyle Morris, M. Pia Morelli, Filip Janku, Michael J. Overman, Bryan K. Kee, David R. Fogelman, Eduardo Vilar Sanchez, Imad Shureiqi, Chris R. Garrett, Kanwal Pratap Singh Raghav, Cathy Eng, Shanequa Manuel, Robert A. Wolff, Helmy Eltoukhy, Richard Burnham Lanman, AmirAli Talasaz, Scott Kopetz. Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients. J Clin Oncol 33(suppl), 2015.
9. David S. Hong, Van Karlyle Morris, Badi Edmond El Osta, Siqing Fu, Michael J. Overman, Sarina Anne Piha-Paul, Vivek Subbiah, Bryan K. Kee, Apostolia Maria Tsimberidou, Ralph Zinner, David R. Fogelman, Jorge Bellido, Imad Shureiqi, Funda Meric-Bernstam, Scott Kopetz. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. J Clin Oncol 33(suppl), 2015.
10. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, Dasari A, Shroff RT, Deaton L, Manuel S, Garrett CR, Vilar Sanchez E, Pini TM, Shureiqi I, Mills GB, Hamilton SR, Wolff RA, Meric-Bernstam F, Abbruzzese JL, Maru DM, Kopetz S. Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: the ATTACC program experience. J Clin Ocol 32(Suppl 3), 2014.
11. Gomes DBD, Hassabo HM, Al Mutar SS, Shain IH, Rogers J, Nguyen DV, Bolonesi RM, Pini TM, Dasari A, Kopetz S. Overman MJ, Eng C, Kee BK, Hassan M, Garrett CR. MD Anderson experience with off-study regorafenib in patients with advanced colorectal cancer. J Clin Oncol 32(Suppl 3), 2014.
12. Lee MS, Overman MJ, Maru DM, Jiang ZQ, Manuel S, Eng C, Kee BK, Fogelman DR, Garrett CR, Advani SM, Vilar Sanchez E, Shureiqi I, Wolff RA, Hamilton SR, Kopetz S. Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer. J Clino Oncol 32(Suppl), 2014.
13. Kopetz, S, Overman MJ, Chen K, Lucio-Eterovic AK, Kee BK, Fogleman DR, Dasari A, Raghav KPS, Vilar Sanchez E, Phillips J, Shureiqi I, Garrett CR, Wolff RA, Patel K, Aldape KD, Luthra R, Routbout M, Maru DM, Meric-Bernstam F, Eng C. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). J Clin Oncol 32(Suppl), 2014.
14. Morelli MP, Overman MJ, Vilar Sanchez E, Morris VK, Shureiqi I, Garrett CR, Fogelman DR, Raghav KPS, Kee BK, Deaton L, Eng C, Wolff RA, Sebisanovic D, Siew LM, Zapanta A, Mei G, Schiller B, Eltoukhy H, Talasaz AA, Kopetz S. Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastic CRC patients. J Clin Oncol 32(Suppl), 2014.
15. Hong DS, Morris VK, Fu S, Overman MJ, Piha-Paul SA, Kee BK, Zinner R, Fogelman DR, Mistry R, Shureiqi I, Meric-Bernstam F, Kopetz S. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. J Clin Oncol 32(Suppl), 2014.
16. Huang HJ, Claes B, Falchook GS, Naing A, Piha-Paul SA, Tsimberidou AM, Zinner R, Karp DD, Fu S, Subbiah V, Hong DS, Wheler JJ, Luthra R, Kee BK, Overman MJ, Kim K, Maertens GG, Kurzrock R, Meric-Bernstam F, Janku F. BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics platform (Idylla). J Clin Oncol 32(Suppl), 2014.
17. Kee BK, Slack R, Crocenzi TS, Wong L, Esparaz B, Overman MJ, Glover KY, Morris J, Fisch M. A phase II, randomized, double blind comparison of calcium aluminosilicate clay (CASAD) versus placebo (dibasic calcium carbonate) for the prevention of diarrhea in patients (pts) with metastatic colorectal cancer (mCRC) treated with irinotecan (I). J Clin Oncol 31(Suppl), 2013.
18. Morelli MP, Overman MJ, Dasari A, Kami SMA, Vilar Sanchez E, Eng C, Kee BK, Deaton L, Garrett CR, Diehl F, Angenendt P, Kopetz S. Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR momoclonal antibodies. J Clin Oncol 31(Suppl), 2013.
19. Bhadkamkar NA, Sahin IH, Shen Y, Hassabo HM, Kee BK, Hassan M Garrett CR. Outcomes in patients (pts) with colorectal cancer (CRC) treated with oxaliplatin-based chemotherapy (OC) following prior oxaliplatin exposure. J Clin Oncol 30(Suppl 34), 2012.
20. Subbiah IM, Blackmon SH, Correa AM, Kee BK, Vaporciyan AA, Swisher S, Eng C. Preoperative chemotherapy prior to pulmonary metastatecomy in patients with prior surgically resected primary colorectal carcinoma. J Clin Oncol 30(Suppl n34), 2012.
21. George B, You Y, Viswanathan, Wen S, Baladandayuthapani V, Overman MJ, Kee BK, Kopetz S, Eng C, Garrett CR. Survival advantage associated with palliative oophorectomy in patietnts with metastatic colorectal cancer (CRC) to the ovaries (mCRC-0): a single institution retrospective analysis. J Clin Oncol 29(Suppl 4), 2011.
22. Hassabo H, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett R. Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM). J Clin Oncol 29(Suppl 4), 2011.
23. Leggas M, Horn J, Tsakalozou E, Moscow JA, Fields SZ, Houchins JC, Eckardt JR, DeSimone P, Kee BK, Rinehart JJ, Arnold SM. Pharmacokinetics (PK) of the highly lipophilic and blood stable camptothecin AR-67 (7-t-butyldimethylsily1-10-hydroxycamptothecin) in adult patients with solid malignancies. J Clin Oncol 27:15S, 2009.
24. Arnold SM, Horn J, Eckardt JR, Rinehart JJ, DeSimone P, Fields SZ, Kee BK, Moscow JA, Houchins JC, Leggas M. Clinical and pharmacokinetic (PK) findings in a phase I study of 7-t-butyldimethylsily1-10-hydroxycamptothecin (AR-67) in patients with refractory solid tumors. J Clin Oncol 27:15S, 2009.